

## **Amendments to the Specification**

Please amend the specification as follows:

Please amend the SEQUENCE LISTING appearing immediately after page 230 of the present application to read as follows:

### SEQUENCE LISTING

<110> **Macrogenics, Inc.**  
Koenig, Scott  
Veri, Maria Concetta

<120> FcGammaRIIB Specific Antibodies and Uses Thereof

<130> ~~11183-003-999~~ **1301.0012CN1**

**<150> 10643857**

**<151> 2003-08-14**

<150> ~~10/524,134~~ **10534124**

<151> 2005-02-11

<150> ~~60/403,266~~ **60403266**

<151> 2002-08-14

**<150> PCT/US03/25399**

**<151> 2003-08-14**

<160> 13

<170> PatentIn version ~~3.2~~ **3.4**

<210> 1

<211> 363

<212> DNA

<213> homo sapiens

<400> 1

cagggtccaat tgcagcagcc tgtgactgag ctggtgaggc cgggggcttc agtgatgttg 60

tcttgcaagg cttctgacta ccccttcacc aactactgga tacactgggt aaagcagagg 120

cctggacaag gcctggagtg gatcggagtg attgatcctt ctgatactta tccaaattac 180

aataaaaagt tcaagggcaa ggccacattg actgtagtcg tatcctccag cacagcctac 240

atgcagctca gcagcctgac atctgacgat tctgcggtct attactgtgc aagaaacggt 300

gattccgatt attactctgg tatggactac tgggggtcaag gaacctcagt caccgtctcc 360

tca 363

<210> 2

<211> 121

<212> PRT

<213> homo sapiens

<400> 2

Gln Val Gln Leu Gln Gln Pro Val Thr Glu Leu Val Arg Pro Gly Ala  
1 5 10 15

Ser Val Met Leu Ser Cys Lys Ala Ser Asp Tyr Pro Phe Thr Asn Tyr  
20 25 30

Trp Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile  
35 40 45

Gly Val Ile Asp Pro Ser Asp Thr Tyr Pro Asn Tyr Asn Lys Lys Phe  
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Val Val Ser Ser Ser Thr Ala Tyr  
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys  
85 90 95

Ala Arg Asn Gly Asp Ser Asp Tyr Tyr Ser Gly Met Asp Tyr Trp Gly  
100 105 110

Gln Gly Thr Ser Val Thr Val Ser Ser  
115 120

<210> 3

<211> 321

<212> DNA

<213> homo sapiens

<400> 3

gacatcttgc tgactcagtc tccagccatc ctgtctgtga gtccaggaga gagagtcagt 60

ttttcctgca ggaccagtca gagcattggc acaaacatac actggtatca gcaaagaaca 120  
aatggttttc caaggcttct cataaagaat gtttctgagt ctatctctgg gatcccttcc 180  
aggtttagtg gcagtggatc agggacagat tttattctta gcatcaacag tgtggagtct 240  
gaagatattg cagattatta ttgtcaacaa agtaatacct ggccggttcac gttcggaggg 300  
gggaccaagc tggaaataaa a 321

<210> 4  
<211> 107  
<212> PRT  
<213> homo sapiens

<400> 4

Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Ser Pro Gly  
1 5 10 15

Glu Arg Val Ser Phe Ser Cys Arg Thr Ser Gln Ser Ile Gly Thr Asn  
20 25 30

Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Phe Pro Arg Leu Leu Ile  
35 40 45

Lys Asn Val Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Ile Leu Ser Ile Asn Ser Val Glu Ser  
65 70 75 80

Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Ser Asn Thr Trp Pro Phe  
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys  
100 105

<210> 5  
<211> 9  
<212> PRT  
<213> artificial

<220>

<223> fusion protein-partial sequence

<400> 5

Lys Lys Phe Ser Arg Ser Asp Pro Asn  
1 5

<210> 6

<211> 9

<212> PRT

<213> artificial

<220>

<223> fusion protein-partial sequence

<400> 6

Gln Lys Phe Ser Arg Leu Asp Pro Asn  
1 5

<210> 7

<211> 9

<212> PRT

<213> artificial

<220>

<223> fusion protein-partial sequence

<400> 7

Gln Lys Phe Ser Arg Leu Asp Pro Thr  
1 5

<210> 8

<211> 9

<212> PRT

<213> artificial

<220>

<223> fusion protein-partial sequence

<400> 8

Lys Lys Phe Ser Arg Leu Asp Pro Thr  
1 5

<210> 9  
<211> 9  
<212> PRT  
<213> artificial  
  
<220>  
<223> fusion protein-partial sequence  
  
<400> 9

~~Gln Lys Phe Ser Arg Leu Asp Pro Thr~~  
Gln Lys Phe Ser His Leu Asp Pro Thr  
1 5

<210> 10  
<211> 9  
<212> PRT  
<213> artificial  
  
<220>  
<223> fusion protein-partial sequence  
  
<400> 10

Lys Lys Phe Ser His Leu Asp Pro Thr  
1 5

<210> 11  
<211> 8  
<212> PRT  
<213> artificial  
  
<220>  
<223> fusion protein-partial sequence

<220>  
<221> MISC\_FEATURE  
<222> (4)..(6)  
<223> X may be any amino acid  
  
<400> 11

Ala Pro Ser Xaa Xaa Xaa Ser Ser  
1 5

<210> 12  
<211> 8  
<212> PRT

<213> artificial

<220>

<223> fusion protein-partial sequence

<400> 12

Val Pro Ser Met Gly Ser Ser Ser  
1 5

<210> 13

<211> 7

<212> PRT

<213> artificial

<220>

<223> FcgammaRIIB2 isoform (positions 135-141)

<400> 13

Ser Asp Pro Asn Phe Ser Ile  
1 5